Notice Pursuant to the National Cooperative Research and Production Act of 1993—Durability and Life Assessment of GTD–111 Buckets

Notice is hereby given that, on October 31, 1995, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), Southwest Research Institute (''SwRI'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are ARCO Alaska, Inc., Anchorage, AK; Exxon Research and Engineering Company, Florham Park, NJ; and, Mobil Exploration & Producing Technical Center, a unit of Mobil Research & Development Corporation, Dallas, TX. The general areas of planned activities are to develop the necessary technology to assess the life of coated gas turbine buckets made from GTD–111 as used in the General Electric line of gas turbines by defining and quantifying the rate of the actual degradation; by developing the properties of these buckets; by developing a life assessment methodology and software program to determine the conditions of the buckets; and by developing nondestructive evaluation (NDE) methods for assessing the coatings. The focus of the program is on the model MS5002 gas turbine.

Membership in the program remains open, and SwRI intends to file additional written notifications disclosing all changes in the membership or planned activities.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 96–26605 Filed 10–16–96; 8:45 am]

BILLING CODE 4410–01–M

Drug Enforcement Administration

[DEA #153P]

Controlled Substances: Proposed Aggregate Production Quotas for 1997

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed aggregate production quotas for 1997.

SUMMARY: This notice proposes initial 1997 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act.

DATES: Comments or objections should be received on or before November 18, 1996.

ADDRESSES: Send comments or objections to the Administrator, Drug Enforcement Administration, Washington, D.C. 20537, Attn: DEA Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537; Telephone: (202) 307–7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

The quotas are to provide adequate supplies of each substance for: (1) the estimated medical, scientific, research, and industrial needs of the United States; (2) lawful export requirements; and (3) the establishment and maintenance of reserve stocks.

In determining the below listed proposed 1997 aggregate production quotas, the Deputy Administrator considered the following factors: (1) total actual 1995 and estimated 1996 and 1997 net disposals of each substance by all manufacturers; (2) estimates of 1996 year end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; (3) product development requirements of both bulk and finished dosage form manufacturers; (4) projected demand as indicated by procurement quota applications filed pursuant to Section 1303.12 of Title 21 of the Code of Federal Regulations and (5) other pertinent information.

Pursuant to Section 1303.23(c) of Title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 1997, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 1996 year-end inventory and actual 1996 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator by Section 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby proposes that the aggregate production quotas for 1997 for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Proposed 1997 quotas
Schedule I:	
2,5-Dimethoxyamphetamine	15,200,100
2,5-Dimethoxy-4-ethylamphetamine (DOET)	2
3-Methylfentanyl	14
3-Methylthiofentanyl	2
3,4-Methylenedioxyamphetamine (MDA)	22
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	27
3,4-Methylenedioxymethamphetamine (MDMA)	7
3,4,5-Trimethoxyamphetamine	2
4-Bromo-2,5-Dimethoxyamphetamine	2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB)	2
4-Methoxyamphetamine	17
4-Methylaminorex	2
4-Methyl-2,5-Dimethoxyamphetamine (DOM)	2